Ieq Capital LLC Invests $3.82 Million in Kura Oncology, Inc. $KURA

Key Points

• Ieq Capital LLC acquired 348,125 shares of Kura Oncology during the second quarter, worth approximately $3.82 million and representing about 0.39% of the company. Other major institutions, including BlackRock, Vanguard and State Street, also increased or initiated positions.
• Analysts remain broadly positive, with 10 Buy ratings, two Holds and one Sell. Kura has a consensus rating of “Moderate Buy” and an average price target of $25.40, compared with a share price of $12.40.
• Kura reported a quarterly loss of $0.77 per share, beating expectations for a $0.88 loss, while revenue of $20.87 million exceeded estimates. The clinical-stage oncology company continues developing targeted cancer therapies, including lead candidate tipifarnib.

Ieq Capital LLC bought a new stake in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 348,125 shares of the company's stock, valued at approximately $3,819,000. Ieq Capital LLC owned approximately 0.39% of Kura Oncology as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. BlackRock Inc. purchased a new position in Kura Oncology during the second quarter worth about $115,286,000. Suvretta Capital Management LLC boosted its holdings in Kura Oncology by 5.7% in the 4th quarter. Suvretta Capital Management LLC now owns 8,575,422 shares of the company's stock valued at $89,099,000 after purchasing an additional 459,422 shares in the last quarter. Vanguard Group Inc. increased its position in Kura Oncology by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 5,507,627 shares of the company's stock worth $57,224,000 after purchasing an additional 39,105 shares during the period. Armistice Capital LLC increased its position in Kura Oncology by 5.7% during the 4th quarter. Armistice Capital LLC now owns 4,936,000 shares of the company's stock worth $51,285,000 after purchasing an additional 264,000 shares during the period. Finally, State Street Corp raised its stake in shares of Kura Oncology by 47.5% during the 4th quarter. State Street Corp now owns 4,931,090 shares of the company's stock worth $51,234,000 after buying an additional 1,587,959 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on KURA. Weiss Ratings restated a "sell (d-)" rating on shares of Kura Oncology in a research note on Friday, July 17th. Morgan Stanley set a $24.00 target price on Kura Oncology in a report on Monday. Sanford C. Bernstein set a $24.00 price target on shares of Kura Oncology in a research note on Monday, June 15th. Raymond James Financial set a $24.00 price target on shares of Kura Oncology in a report on Monday. Finally, Oppenheimer set a $24.00 price objective on shares of Kura Oncology in a research note on Thursday, May 28th. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $25.40.

Kura Oncology Stock Performance

KURA opened at $12.40 on Tuesday. Kura Oncology, Inc. has a 1-year low of $7.36 and a 1-year high of $12.90. The stock has a market cap of $1.10 billion, a P/E ratio of -3.68 and a beta of 0.38. The stock's 50 day simple moving average is $10.59 and its 200 day simple moving average is $9.50. The company has a debt-to-equity ratio of 0.12, a current ratio of 4.73 and a quick ratio of 4.71.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.11. The firm had revenue of $20.87 million during the quarter, compared to analysts' expectations of $20.16 million. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%. As a group, equities analysts anticipate that Kura Oncology, Inc. will post -3.23 EPS for the current fiscal year.

Insider Transactions at Kura Oncology

In related news, insider Mollie Leoni sold 84,929 shares of the business's stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $9.82, for a total value of $834,002.78. Following the sale, the insider directly owned 182,345 shares in the company, valued at $1,790,627.90. The trade was a 31.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Brian T. Powl sold 4,345 shares of the stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $11.89, for a total transaction of $51,662.05. Following the completion of the sale, the insider directly owned 169,269 shares in the company, valued at approximately $2,012,608.41. The trade was a 2.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 120,761 shares of company stock worth $1,283,346. Corporate insiders own 7.60% of the company's stock.

About Kura Oncology

Kura Oncology, Inc NASDAQ: KURA is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura's research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company's lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.

Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology, Inc. (NASDAQ:KURA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source